Invesco Ltd. Has $403,000 Position in REGENXBIO Inc. (NASDAQ:RGNX)

Invesco Ltd. decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 61.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,128 shares of the biotechnology company's stock after selling 84,036 shares during the period. Invesco Ltd. owned about 0.11% of REGENXBIO worth $403,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the period. Norges Bank acquired a new position in REGENXBIO during the 4th quarter valued at about $3,474,000. Assenagon Asset Management S.A. boosted its stake in shares of REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of REGENXBIO during the 4th quarter worth approximately $1,160,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of REGENXBIO during the fourth quarter worth approximately $1,062,000. Institutional investors own 88.08% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. HC Wainwright cut their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. The Goldman Sachs Group decreased their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, Morgan Stanley increased their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Stock Performance

NASDAQ RGNX traded down $0.68 during trading on Wednesday, hitting $7.24. The stock had a trading volume of 1,938,874 shares, compared to its average volume of 836,274. The company has a market capitalization of $362.85 million, a PE ratio of -1.44 and a beta of 1.11. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $17.35. The company's 50-day moving average price is $7.25 and its two-hundred day moving average price is $8.06.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, equities analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.